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The prevalence and clinical relevance of p27 and cyclin
E immunoreactivity in myelodysplastic syndromes
We report on p27 and cyclin E immunoreactivity (IR) in
86 patients with myelodysplastic syndromes (MDS). No
association was found between cyclin E IR and survival in
the whole series. Cyclin E IR was more prevalent in patients
with refractory anemia (RA) and RA with ringed sideroblasts
(RARS) with poor survival, although this trend was not sta-
tistically significant.
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Genetic alterations of the cell cycle regulators p27 and
cyclin E have never been reported in hematopoietic malig-
nancies, but their abnormal expression is associated with a
poor prognosis in non-Hodgkin's lymphomas1 and acute
myeoid leukemia (AML).2 We immunohistochemically analyzed
p27 and cyclin E immunoreactivity in nitric acid-decalcified,
Bouin-fixed and paraffin-embedded bone marrow biopsies of
86 MDS patients (23 with RA, 10 with RARS, 39 with RA with
excess blasts (RAEB), 6 with RAEB in transformation (RAEB-
t), and 8 with chronic myelomonocytic leukemia (CMML). Sev-
enty-eight consecutive patients were retrieved from the files
of the Ospedale Maggiore, the only inclusion criterion being
the availability of a bone marrow biopsy at diagnosis. The
remaining eight patients were retrieved from the 1999 files of
S. Raffaele Hospital Scientific Institute, and selected accord-
ing to the availability of a bone marrow biopsy at diagnosis
and subsequent development of acute myeloid leukemia. Over-
all, there were 45 males and 41 females with a mean age of
66 years (range 18-86). The follow-up was available for 76
(88.3%) patients and its mean time was 56.7 months (range
1.1-149.0). Thirty-nine patients (45.3%) progressed to AML in
a mean time of 29 months (1-79). Thirty-seven (48.6%)
patients died because of their disease and 39 were alive with
disease. IR for p27 and cyclin E was assayed by means of the
ABC method with the anti-p27 57 (Transduction Laboratories)
and anti-cyclin E 13A3 (Novocastra Laboratories) monoclon-
al antibodies (working dilution: 1:200 and 1:50, respectively).
At least 500 cells were evaluated at x1000 magnification, and
only nuclear staining was considered positive. Control exper-
iments were performed on normal bone marrow biopsies from
ten Italian patients (three men and seven women, mean age
52 years) with localized solid tumors (six with infiltrating duct
carcinoma of the breast and four with small cell carcinoma of
the lung). For statistical purposes, the threshold for the vari-
ables of hemoglobin, M/E ratio and cyclin E IR was established
according to their median values in MDS (Table 1). The asso-
ciations between the clinico-pathologic and immunohisto-
chemical data were evaluated by the Mann-Whitney test, χ2
test or Fisher’s exact test. Survival estimates were calculated
with Kaplan-Meier's method and compared by the log-rank
test. The Cox proportional hazard regression model was used
to evaluate the simultaneous effect of explanatory variables
on survival time.
In normal bone marrow, IR for p27 was detected in endothe-
lial cells, lymphocytes, plasma cells and in the vast majority
(mean 85%, standard deviation ±8%) of megakaryocytes,
whereas erythroid and myeloid cells were invariably unreac-
tive, a finding in keeping with previous studies.3 In MDS, ery-
throid and myeloid cells were also unreactive and p27 IR was
detectable in most of the dysplastic megakaryocytes, although
to a lesser extent than in normal controls (78±16%, p=0.177).
In normal bone marrow, cyclin E IR was detectable in a very
small fraction (4±1%) of intermediate and immature cells of
the erythroid and myeloid lineages,4,5 whereas megakaryocytes
were always unreactive. In MDS, the percentage of immunore-
active cells was significantly higher (10±7% vs. 4±1%,
p=0.008). In particular, the values of cyclin E IR were 9±7%
in RA, 13±10% in RARS, 11±7% in RAEB, 7±7% in RAEB-t and
6±3% in CMML. The RA (p=0.014), RARS (p=0.011) and RAEB
(p=0.003), but not RAEB-t (p=0.194) and CMML (p=0.064)
subtypes had values of cyclin E IR significantly higher than
those in normal controls. There was a significant difference in
cyclin E IR between CMML and the other MDS subtypes (6±3
vs. 11±7, p=0.028), and not among the subtypes of RA, RARS,
RAEB and RAEB-t (p=0.418), a finding in line with the notion
that CMML represents a disorder distinct from MDS.6 Cyclin E
has been recently identified as a target for activation by ion-
izing radiation, playing a functional role in apoptosis of
hematopoietic cells.7 This finding leads to speculation that
cyclin E up-regulation may contribute to ineffective hema-
topoiesis in MDS by trigging apoptosis, a pathway that is acti-
vated in these disorders, particularly in RA/RARS subtypes.8 At
univariate analysis, no significant association was found
between cyclin E IR, risk of progression (p=1.000) or time to
progression (p=0.587) towards AML.
No significant correlation was found between cyclin E IR
and the clinico-pathologic variables analyzed. At univariate
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Table 1. Univariate analysis (Kaplan-Meier) in the whole
series.
Patients Deaths Log-rank
Gender
Males 40 24
Females 36 13 0.0257
Age
<60 25 10
≥60 51 27 0.3236
IPSS1
Low/INT-1 45 13
INT-2/High 23 20 <0.0001
Myeloblasts
<5% 28 4
5-10% 28 16
>10% 20 17 <0.0001
Hb2
<10.7 35 19
≥10.7 37 17 0.5317
M/E3 ratio
<1.35 34 11
≥1.35 36 24 0.0011
Cyclin E IR4
<9% 37 18
≥9% 39 19 0.8751
FAB subtype
RA 18 2
RARS 10 4
RAEB 36 21
RAEB-t 4 4
CMML 8 6 <0.0001
Karyotype
46, XX/XY 36 14
Others 40 23 0.1197
1International Prognostic Scoring System;2Hemoglobin g/dL;
3Myeloid/erythroid ratio;4Immunoreactivity.
analysis, the International Prognostic Scoring System (IPSS),9
percentage of blasts, M/E ratio, FAB subtype, but not cyclin E
IR, were significantly associated with survival (Table 1). Mul-
tivariate analysis showed that IPSS (p=0.0068) and RAEB-t
subtype (p=0.001) were independent predictors of survival.
Interestingly, when the survival analysis was restricted to the
low-risk subset of RA/RARS, the variables of age (p=0.0287),
IPSS (p=0.0113) and FAB subtype (RA vs. RARS, p=0.0563)
were associated with survival. At multivariate analysis, the
variable of age (p=0.0284) was the only independent predic-
tor of survival in RA/RARS. Although cyclin E IR was more
prevalent in RA/RARS with an adverse clinical course, this
trend did not achieve statistical significance, either at uni-
variate (p=0.0759), or multivariate (p=0.0604) analysis, pos-
sibly because of the relatively small number of cases.
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Incidence of trisomy 8 and 9, deletion of D13S319
and D20S108 loci and BCR/ABL translocation in
non-treated essential thrombocythemia patients: an
analysis of bone marrow cells using interphase
fluorescence in situ hybridization
We compare conventional cytogenetics (CC) with fluo-
rescence in situ hybridization (FISH) in 53 untreated
patients with essential thrombocythemia. CC revealed no
abnormalities. When FISH was used, no BCR/ABL rearrange-
ment nor trisomy 8 was found, but one trisomy 9, two
del(13)(q14) and five del(20)(q12) were observed. FISH
detected chromosome abnormalities in 15% of patients in
which no alteration was found by CC.
Haematologica 2003;88:110-111
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Essential thrombocythemia (ET) is a chronic myeloprolifera-
tive disorder (CMPD) with megakaryocytic proliferation in bone
marrow resulting in a persistent increase in platelets in periph-
eral blood. In ET patients chromosome abnormalities detected
by G-banding are rare, and no specific abnormality has been
identified.1 Only about 5% of patients show an abnormal kary-
otype at diagnosis.2 The most frequent cytogenetic anomalies
detected by conventional cytogenetics (CC) are trisomies of
chromosomes 8 and 9 and deletions in 13q and 20q.1
The finding of an abnormal karyotype would be useful to dis-
tinguish ET from secondary thrombocytosis as it gives a clonal
hallmark to the disease. For this reason, we re-evaluated genet-
ic findings obtained by CC using fluorescence in situ hybridiza-
tion (FISH) probes, with the aim of yielding more information
about chromosomal abnormalities in ET patients.
Herein, we present 53 cases diagnosed as having ET accord-
ing to the Polycythemia Vera Study Group (PVSG) criteria3 and
who had not previously received cytolytic treatment. Samples
from ten healthy volunteers were used as assay validation con-
trols. Chromosome analyses were carried out on hematologic
cells from 24-hour bone marrow cultures. Karyotypes were
described according the International System for Human Cyto-
genetic Nomenclature.4
FISH studies were performed on fixed nuclei from CC fol-
lowing the standard procedures (Table 1). CC results were avail-
able in 49/53 patients, all showing a normal karyotype; in the
remaining four cases no metaphases were obtained. When FISH
was performed, no patient showed BCR/ABL rearrangement nor
trisomy 8. One patient showed trisomy 9 in 30% of studied
cells, in 2/53 patients a 13q14 deletion was found (frequencies
16% to 26.5%) and 5/53 patients presented a 20q12 deletion
(frequencies 10.5% to 13.5%). Both monosomies were hemizy-
gous. There were no cases with more than one abnormality.
FISH probes detected chromosomal abnormalities in 8/53 ET
patients (15.1%) (Table 2).
FISH studies have been done in ET patients in order to search
for chromosome 8 and 9 abnormalities.5,6 Elis et al.5 reported
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